Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IAPP | P10997 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486603 | 1.00 | GLA (0.44) | GLATDP1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL1775432 | 0.84 | KMT2A (0.56) | KMT2AMAPK1ALDH1A1KDM4ECES2 | |
| SCHEMBL1775435 | 0.84 | KMT2A (0.56) | KMT2AMAPK1ALDH1A1KDM4ECES2 | |
| SCHEMBL28774607 | 0.82 | CES2 (0.41) | KMT2AMAPK1ALDH1A1KDM4ECES2 | |
| SCHEMBL68057 | 0.82 | CA12 (0.46) | KMT2AMAPK1ALDH1A1KDM4ERAB9A | |
| SCHEMBL3475868 | 0.82 | ALDH1A1 (0.45) | KMT2AMAPK1ALDH1A1KDM4ECES2 | |
| SCHEMBL68058 | 0.82 | CA12 (0.46) | KMT2AMAPK1ALDH1A1KDM4ERAB9A | |
| SCHEMBL17157651 | 0.81 | DAO (0.42) | KMT2AMAPK1ALDH1A1KDM4ECES2 | |
| SCHEMBL17157652 | 0.81 | DAO (0.42) | KMT2AMAPK1ALDH1A1KDM4ECES2 | |
| SCHEMBL17158027 | 0.79 | RAB9A (0.39) | KMT2AMAPK1ALDH1A1KDM4ECES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022158624-A1 | NOVEL BENZOPYRAN DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND ANTICANCER COMPOSITION COMPRISING SAME | 연세대학교 산학협력단 | 2022-07-28 | — | — | WO | disclosed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1615898-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | Novartis AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089913-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | GLA 3101/4885TDP1 478/4885KMT2A 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.